medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2023, Número 2

Siguiente >>

Cir Card Mex 2023; 8 (2)


COAPT trial in the current era. Apertis verbis still much to be clarified

García-Villarreal OA

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 25-28
Archivo PDF: 148.44 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Giustino G, Camaj A, Kapadia S, et al. Hospitalizations and Mortality in Patientswith Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial. J AmColl Cardiol. 2022, 80 (20) 1857–1868. doi: 10.1016/j.jacc.2022.08.803

  2. Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. TranscatheterMitral-Valve Repair in Patients with Heart Failure. N Engl J Med.2018;379(24):2307-2318. doi: 10.1056/NEJMoa1806640.

  3. García-Villarreal OA. Chasm between the Guided-Directed Medical Therapy forfunctional mitral regurgitation used in the COAPT trial and present time: a majorrevision is mandatory. Cir Card Mex 2022; 7(4): 61-64.

  4. Iung B, Armoiry X, Vahanian A, et al; MITRA-FR Investigators. Percutaneous repairor medical treatment for secondary mitral regurgitation: outcomes at 2 years.Eur J Heart Fail. 2019;21(12):1619-1627. doi: 10.1002/ejhf.1616.

  5. García-Villarreal OA. Transcatheter Edge-to-Edge Mitral Valve Repair in FunctionalMitral Regurgitation. Does it Pass Muster? Still Leaving Plenty to Be Desired.Braz J Cardiovasc Surg. 2022;37(2):I-IV. doi: 10.21470/1678-9741-2022-0129.

  6. García-Villarreal OA. Transcatheter edge-to-edge valve repair in functional mitralregurgitation. Eur J Cardiothorac Surg. 2022;62(2):ezab521. doi: 10.1093/ejcts/ezab521.

  7. Grayburn PA, Sannino A, Packer M. Proportionate and Disproportionate FunctionalMitral Regurgitation: A New Conceptual Framework That Reconciles theResults of the MITRA-FR and COAPT Trials. JACC Cardiovasc Imaging. 2019Feb;12(2):353-362. doi: 10.1016/j.jcmg.2018.11.006.

  8. Hagendorff A, Knebel F, Helfen A, Stöbe S, Doenst T, Falk V. Disproportionatemitral regurgitation: another myth? A critical appraisal of echocardiographicassessment of functional mitral regurgitation. Int J Cardiovasc Imaging. 2021Jan;37(1):183-196. doi: 10.1007/s10554-020-01975-6.

  9. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for theManagement of Patients with Valvular Heart Disease: Executive Summary:A Report of the American College of Cardiology/American Heart AssociationJoint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932.

  10. Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group.2021 ESC/EACTS Guidelines for the management of valvular heart disease. EurJ Cardiothorac Surg. 2021 Oct 22;60(4):727-800. doi: 10.1093/ejcts/ezab389.

  11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trendsin preva-lence and outcome of heart failure with preserved ejection fraction. NEngl J Med. 2006;355(3):251-9. doi: 10.1056/NEJMoa052256.

  12. Varadarajan P, Sharma S, Heywood JT, Pai RG. High prevalence of clinicallysilent severe mitral regurgitation in patients with heart failure: role for echocardiography.J Am Soc Echocardiogr. 2006;19(12):1458-61. doi: 10.1016/j.echo.2006.06.009.

  13. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline forthe Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063.

  14. Nasser R, Van Assche L, Vorlat A, et al. Evolution of Functional Mitral Regurgitationand Prognosis in Medically Managed Heart Failure Patients with ReducedEjection Fraction. JACC Heart Fail. 2017;5(9):652-659. doi: 10.1016/j.jchf.2017.06.015.

  15. Januzzi JL, Omar AMS, Liu Y, et al. Association Between Sacubitril/ValsartanInitiation and Mitral Regurgitation Severity in Heart Failure with Reduced EjectionFraction: The PROVE-HF Study. Circulation. 2022;146(21):1638-1640. doi:10.1161/CIRCULATIONAHA.122.061693.

  16. Ezekowitz JA. Residuals: Mitral Regurgitation, Bias, and Effects of MedicalTherapy. Circulation. 2021;144(6):438-440. doi:10.1161/CIRCULATIONAHA.121.055707.

  17. DeFilippis EM, Fiuzat M. Putting the "Optimal" in Optimal Medical Therapy.JACC Heart Fail. 2021;9(1):39-41. doi: 10.1016/j.jchf.2020.08.016.

  18. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure withReduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.

  19. Greene SJ, Fonarow GC, DeVore AD, et al. Titration of Medical Therapy for HeartFailure with Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015.

  20. Fiuzat M, Ezekowitz J, Alemayehu W, et al. Assessment of Limitations to Optimizationof Guideline-Directed Medical Therapy in Heart Failure From the GUIDEITTrial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol.2020;5(7):757-764. doi: 10.1001/jamacardio.2020.0640.

  21. Supplementary Appendix to: Stone GW, Lindenfeld JA, Abraham WT, et al.Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med2018;379:2307-18. DOI: 10.1056/NEJMoa1806640.

  22. Lindfield J, et al. J Am Coll Cardiol. 2020, 75 (11_Supplement_1) 973 (Abstract2020).

  23. Cox ZL, et al. Maximally-tolerated guideline-directed medical therapy and barriersto optimizationi in patients with HF with HFrEF: The COAPT trial. (2022,Abstract ESC 2022).

  24. Buzzatti N, De Bonis M, Denti P, et al. What is a "good" result after transcathetermitral repair? Impact of 2+ residual mitral regurgitation. J Thorac CardiovascSurg. 2016;151(1):88-96. doi: 10.1016/j.jtcvs.2015.09.099.

  25. Reichart D, Kalbacher D, Rübsamen N, et al. The impact of residual mitral regurgitationafter MitraClip therapy in functional mitral regurgitation. Eur J Heart Fail.2020;22(10):1840-1848. doi: 10.1002/ejhf.1774.

  26. Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, Öztürk C, Weber M, Tabata N,Zimmer S, Sinning JM, Mauri V, et al. Recurrent Mitral Regurgitation After Mitra-Clip: Predictive Factors, Morphology, and Clinical Implication. Circ CardiovascInterv. 2022;15(3):e010895. doi: 10.1161/CIRCINTERVENTIONS.121.010895.

  27. Arnold SV, Chinnakondepalli KM, Spertus JA,; COAPT Investigators. HealthStatus After Transcatheter Mitral-Valve Repair in Heart Failure and SecondaryMitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2019;73(17):2123-2132.doi: 10.1016/j.jacc.2019.02.010.

  28. van Wijngaarden SE, Kamperidis V, Al-Amri I, et al. Effects of TranscatheterMitral Valve Repair with MitraClip on Left Ventricular and Atrial HemodynamicLoad and Myocardial Wall Stress. J Card Fail. 2018;24(3):137-145. doi:10.1016/j.cardfail.2017.12.008.

  29. Fine NM, McAlister FA, Howlett JG, Youngson E, Ezekowitz JA. Low Prevalenceof Transcatheter Mitral Valve Repair Eligibility in a Community Heart FailurePopulation. Circ Heart Fail. 2020;13(5):e006952. doi: 10.1161/CIRCHEARTFAILURE.120.006952.




2020     |     www.medigraphic.com